What Does Smith & Nephew (SNN) Do? – Stock Outlook, Earnings, Market Cap, Related Stocks, and Headquarters Overview
Smith & Nephew (SNN) is the ADR of a global medical-device company supplying orthopedic implants, sports medicine devices, and wound care products. Aging-driven surgical demand, new product launches, and business efficiency initiatives are the key drivers of its earnings and stock outlook.
Subscribe🏢 What kind of company is Smith & Nephew?
Smith & Nephew (SNN) is a UK-based global medical-device company that makes orthopedic implants, sports medicine devices, and wound care products. It is listed on the US stock market through an American Depositary Receipt (ADR), and it focuses on the medical-device sector, which benefits from population aging and rising surgical demand.
Its business is divided into three segments: Orthopedics (hip and knee implants), Sports Medicine & ENT, and Wound Care. Orthopedic implants such as artificial joints form the core, complemented by arthroscopic surgical devices and chronic wound care products. Its primary customers are hospitals and surgeons, and surgical demand driven by aging populations provides a structural growth foundation.
💰 How does Smith & Nephew make money?
| Business Segment | Revenue Share | Description |
|---|---|---|
| Orthopedics | Core | The largest segment by revenue, comprising hip and knee implants and other orthopedic products |
| Sports Medicine & ENT | Expanding | Arthroscopic surgical devices and other sports medicine and ENT products |
| Wound Care | Diversification Pillar | Products for chronic wound and surgical-site care |
Orthopedic products such as artificial joints account for the largest share of Smith & Nephew's revenue, with sports medicine and wound care supplementing it. Rising demand for joint replacement surgeries driven by population aging provides a stable growth foundation, while consumable-type wound care products add recurring revenue. The company is pursuing growth through new product launches and emerging-market expansion, while implementing business efficiency initiatives and restructuring to improve its previously slower growth and profitability.
📐 Smith & Nephew Market Cap and Company Scale
Market capitalization is $11.5B, and employee headcount is not publicly disclosed.
As a company specializing in orthopedics, sports medicine, and wound care within the global medical-device market, it offers a broad product portfolio and a hospital/surgeon customer base. It is supported by the structural demand driver of population aging and is in a phase of lifting growth and profitability through new products, emerging-market expansion, and business efficiency initiatives.
📈 Smith & Nephew Outlook and Stock Price Trend
1-Year Price Performance
Analyst Consensus
52-Week Price RangeMedium- to long-term drivers include rising demand for joint replacement surgeries driven by aging populations, new product launches, and emerging-market expansion. Population aging is a positive structural force driving a steady increase in orthopedic procedures such as artificial joint replacement. The company is working to improve profitability through business efficiency initiatives and restructuring. On the other hand, intensifying competition with large rivals, healthcare reimbursement policies and hospital budgets, currency fluctuations, and uncertainty around restructuring outcomes may act as short-term earnings variables.
- Rising demand for joint replacement surgeries driven by aging populations
- New product launches and emerging-market expansion
- Profitability improvement through business efficiency initiatives and restructuring
⚔️ Smith & Nephew Key Strengths and Risks
Aging-driven demand, a broad product portfolio, and room for efficiency gains are key strengths, while intensifying competition, healthcare reimbursement policy, and uncertainty around restructuring outcomes are core risks.
💪 Key Strengths
⚠️ Key Risks
🔄 Smith & Nephew Competitors and Related Stocks (Beneficiaries)
In the medical-device space, Smith & Nephew is compared alongside other large medical-device companies. Orthopedic device maker ZBH, orthopedic and surgical device maker SYK, and diversified medical-device maker MDT are cited as direct comparables whose business areas overlap.
Competitors| Ticker | Company | Price | Change | Market Cap | P/E | PBR | ROE | Dividend Yield |
|---|---|---|---|---|---|---|---|---|
 ZBH | Zimmer Biomet Holdings Inc | $93.49 | +1.1% | $17.8B | 22.8 | 1.4 | 6.42% | 1.11% |
| SYK | Stryker Corp | $275.56 | +2.1% | $105.7B | 28.6 | 4.4 | 16.51% | 1.28% |
| MDT | Medtronic Plc | $90.96 | -0.7% | $116.4B | 22.4 | 2.3 | 10.66% | 3.18% |
✅ Investor Checklist for Smith & Nephew
Smith & Nephew is the ADR of a global medical-device company supplying artificial joints, sports medicine devices, and wound care products. Aging-driven demand and a broad product portfolio are appealing, but investors should also monitor intensifying competition and restructuring outcomes. Surgical Demand: Orthopedic surgical demand driven by aging populations — Structural Growth Efficiency: Profitability improvement through business efficiency initiatives and restructuring — Key Variable Competition and Policy: Large competitors and healthcare reimbursement policies — Profitability Variable Intensifying competition with large medical-device companies, changes in reimbursement policies and hospital budgets, currency fluctuations, and uncertainty around restructuring outcomes may affect earnings, so progress on surgical demand and profitability improvement should be monitored together. Smith & Nephew is a global medical-device company with aging-driven demand, a broad product portfolio, and efficiency upside, but given intensifying competition, healthcare policy, and restructuring uncertainty, a medium- to long-term perspective is advisable.
Subscribe Today's 5 AI picks, all free